Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1

IntroductionMatching patients to an effective targeted therapy or immunotherapy is a challenge for advanced and metastatic non-small cell lung cancer (NSCLC), especially when relying on assays that test one marker at a time. Unlike traditional single marker tests, comprehensive genomic profiling (CG...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Zachary D. Wallen, Mary K. Nesline, Marni Tierno, Alison Roos, Erica Schnettler, Hatim Husain, Pratheesh Sathyan, Brian Caveney, Marcia Eisenberg, Eric A. Severson, Shakti H. Ramkissoon
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2024-11-01
coleção:	Frontiers in Oncology
Assuntos:	non-small cell lung cancer genomic profiling immune checkpoint inhibitors TMB PD-L1 clinical utility
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1473327/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!